ReviewFrontiers in endocrinology2021
Gut Microbiota in Adipose Tissue Dysfunction Induced Cardiovascular Disease: Role as a Metabolic Organ.
Review in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Prevalence of metabolic syndrome in patients with inflammatory bowel disease: a meta-analysis on a global scale.Journal of health, population, and nutrition · 2025Pooled it
- Alteration in Gut Microbiota Composition of Older Adults Is Associated with Obesity and Its Indices: A Systematic Review.The journal of nutrition, health & aging · 2023Pooled it
- Gut-reproduction axis: a new perspective on understanding pelvic inflammatory disease.Frontiers in microbiology · 2026Review
- Functional Beverages From Frankincense andFood science & nutrition · 2025Article
- Dissecting the role of gut microbiota heterogeneity in the onset of chronic lung diseases.AMB Express · 2025Article
- Gut-Adipose Tissue Axis and Metabolic Health.Current issues in molecular biology · 2025Review
- Chronic inflammation in obesity and neurodegenerative diseases: exploring the link in disease onset and progression.Molecular biology reports · 2025Review
- Gut microbiota: emerging biomarkers and potential therapeutics for premature ovarian failure.Frontiers in microbiology · 2025Review
- Gut microbiota on cardiovascular diseases-a mini review on current evidence.Frontiers in microbiology · 2025Review
- The role of gut microbiota dysbiosis in the inflammatory pathogenesis of diabetic retinopathy.Frontiers in immunology · 2025Review
- Applied physiology: gut microbiota and antimicrobial therapy.European journal of applied physiology · 2024Review
- Secrets and lies of host-microbial interactions: MHC restriction and trans-regulation of T cell trafficking conceal the role of microbial agents on the edge between health and multifactorial/complex diseases.Cellular and molecular life sciences : CMLS · 2024Review
- The footprint of gut microbiota in gallbladder cancer: a mechanistic review.Frontiers in cellular and infection microbiology · 2024Review
- Obstructive Sleep Apnea Syndrome and Obesity Indicators, Circulating Blood Lipid Levels, and Adipokines Levels: A Bidirectional Two-Sample Mendelian Randomization Study.Nature and science of sleep · 2024Article
- Captivity conditions matter for the gut microbiota of an endangered obligate hibernator.Conservation physiology · 2024Article
- Effect of Gut Microbiota on the Pharmacokinetics of Nifedipine in Spontaneously Hypertensive Rats.Pharmaceutics · 2023Article
- The Prebiotic Effects of an Extract with Antioxidant Properties fromAntioxidants (Basel, Switzerland) · 2023Article
- Article
- Revitalizing myocarditis treatment through gut microbiota modulation: unveiling a promising therapeutic avenue.Frontiers in cellular and infection microbiology · 2023Review
- Brain-to-BAT - and Back?: Crosstalk between the Central Nervous System and Thermogenic Adipose Tissue in Development and Therapy of Obesity.Brain sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiome has emerged as a key regulator of host metabolism. Accumulating evidence has indicated that the gut microbiota is involved in the development of various human diseases. This association relies on the structure and metabolites of the gut microbiota. The gut microbiota metabolizes the diet ingested by the host into a series of metabolites, including short chain fatty acids, secondary bile acids, trimethylamine N-oxide, and branched-chain amino acids, which affects the physiological processes of the host by activating numerous signaling pathways. In this review, we first summarize the various mechanisms through which the gut microbiota influences adipose tissue dysfunction and metabolic processes that subsequently cause cardiovascular diseases, highlighting the complex interactions between gut microbes, their metabolites, and the metabolic activity of the host. Furthermore, we investigated the current status of clinical therapies for adipose tissue dysfunction directed at the gut microbiota. Finally, we discuss the challenges that remain to be addressed before this field of research can be translated to everyday clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.